The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 03, 2012
Filed:
May. 09, 2005
Mark S. Smyth, San Mateo, CA (US);
Guy J. Laidig, Menlo Park, CA (US);
Ronald T. Borchardt, Lawrence, KS (US);
Barry A. Bunin, San Mateo, CA (US);
Craig M. Crews, New Haven, CT (US);
John H. Musser, San Carlos, CA (US);
Kevin D. Shenk, Palo Alto, CA (US);
Peggy A. Radel, Berkeley, CA (US);
Mark S. Smyth, San Mateo, CA (US);
Guy J. Laidig, Menlo Park, CA (US);
Ronald T. Borchardt, Lawrence, KS (US);
Barry A. Bunin, San Mateo, CA (US);
Craig M. Crews, New Haven, CT (US);
John H. Musser, San Carlos, CA (US);
Kevin D. Shenk, Palo Alto, CA (US);
Peggy A. Radel, Berkeley, CA (US);
Onyx Therapeutics, Inc., South San Francisco, CA (US);
Abstract
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.